BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017;166:637-648. [PMID: 28319996 DOI: 10.7326/m16-2575] [Cited by in Crossref: 327] [Cited by in F6Publishing: 148] [Article Influence: 65.4] [Reference Citation Analysis]
Number Citing Articles
1 Jia Y, Yue W, Gao Q, Tao R, Zhang Y, Fu X, Liu Y, Liu L, Feng Y, Xia X. Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China. Microbiol Spectr 2021;9:e0029721. [PMID: 34479413 DOI: 10.1128/Spectrum.00297-21] [Reference Citation Analysis]
2 Luxenburger H, Neumann-Haefelin C, Thimme R, Boettler T. HCV-Specific T Cell Responses During and After Chronic HCV Infection. Viruses 2018;10:E645. [PMID: 30453612 DOI: 10.3390/v10110645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
3 Voils CI, King HA, Thorpe CT, Blalock DV, Kronish IM, Reeve BB, Boatright C, Gellad ZF. Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment. Dig Dis Sci 2019;64:2784-97. [PMID: 31037593 DOI: 10.1007/s10620-019-05621-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc. 2017;20:22146. [PMID: 28782335 DOI: 10.7448/ias.20.1.22146] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 14.8] [Reference Citation Analysis]
5 Calise SJ, Zheng B, Hasegawa T, Satoh M, Isailovic N, Ceribelli A, Andrade LEC, Boylan K, Cavazzana I, Fritzler MJ, de la Torre IG, Hiepe F, Kohl K, Selmi C, Shoenfeld Y, Tincani A, Chan EKL; IUIS Autoantibody Standardization Committee. Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. Clin Chem Lab Med 2018;56:1789-98. [PMID: 29478040 DOI: 10.1515/cclm-2017-1152] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
6 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Reference Citation Analysis]
7 Chang SH, Merzkani M, Lentine KL, Wang M, Axelrod DA, Anwar S, Schnitzler MA, Wellen J, Chapman WC, Alhamad T. Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States. Clin J Am Soc Nephrol 2021;16:251-61. [PMID: 33451990 DOI: 10.2215/CJN.10960720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Cho HJ, Park E. Development and Evaluation of an Antiviral Agent Medication Adherence Education Program for Patients with Chronic Hepatitis C. Int J Environ Res Public Health 2020;17:E6518. [PMID: 32906842 DOI: 10.3390/ijerph17186518] [Reference Citation Analysis]
9 Madden A, Hopwood M, Neale J, Treloar C. Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduct J 2018;15:42. [PMID: 30111327 DOI: 10.1186/s12954-018-0248-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
10 Nakamura F, Takeda H, Ueda Y, Takai A, Takahashi K, Eso Y, Arasawa S, Iguchi E, Shimizu T, Mishima M, Kumagai K, Yamashita T, Uemoto S, Kato N, Marusawa H, Sekine A, Seno H. Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing. Sci Rep 2022;12:7083. [PMID: 35490163 DOI: 10.1038/s41598-022-11151-6] [Reference Citation Analysis]
11 Kazmierski WM, Miriyala N, Johnson DK, Baskaran S. The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors. ACS Med Chem Lett 2021;12:1649-55. [PMID: 34790290 DOI: 10.1021/acsmedchemlett.1c00391] [Reference Citation Analysis]
12 Falade-Nwulia O, Gicquelais RE, Astemborski J, McCormick SD, Kirk G, Sulkowski M, Thomas DL, Mehta SH. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Liver Int 2020;40:2407-16. [PMID: 32770638 DOI: 10.1111/liv.14634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. Euro Surveill 2019;24. [PMID: 31362808 DOI: 10.2807/1560-7917.ES.2019.24.30.1800614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
14 Zhou B, Cai GFF, Lv HKK, Xu SFF, Wang ZTT, Jiang ZGG, Hu CGG, Chen YDD. Factors Correlating to the Development of Hepatitis C Virus Infection among Drug Users-Findings from a Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2019;16:E2345. [PMID: 31269774 DOI: 10.3390/ijerph16132345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Liu TM, Wang H, Zhang DN, Zhu GZ. Transcription Factor MafB Suppresses Type I Interferon Production by CD14+ Monocytes in Patients With Chronic Hepatitis C. Front Microbiol 2019;10:1814. [PMID: 31447817 DOI: 10.3389/fmicb.2019.01814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Lourenço MS, Zitelli PMY, Cunha-Silva M, Oliveira AIN, Oliveira CP, Sevá-Pereira T, Carrilho FJ, Pessoa MG, Mazo DF. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. World J Hepatol 2022; 14(1): 195-208 [DOI: 10.4254/wjh.v14.i1.195] [Reference Citation Analysis]
17 Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. Structure 2018;26:1360-1372.e5. [PMID: 30146168 DOI: 10.1016/j.str.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
18 Neukam K, Martínez AP, Culasso ACA, Ridruejo E, García G, Di Lello FA. NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b. PLoS One 2017;12:e0182193. [PMID: 28753662 DOI: 10.1371/journal.pone.0182193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
19 Matthew AN, Leidner F, Lockbaum GJ, Henes M, Zephyr J, Hou S, Rao DN, Timm J, Rusere LN, Ragland DA, Paulsen JL, Prachanronarong K, Soumana DI, Nalivaika EA, Kurt Yilmaz N, Ali A, Schiffer CA. Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Chem Rev 2021;121:3238-70. [PMID: 33410674 DOI: 10.1021/acs.chemrev.0c00648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Skolnik AA, Noska A, Yakovchenko V, Tsai J, Jones N, Gifford AL, McInnes DK. Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes. BMC Health Serv Res 2019;19:91. [PMID: 30709352 DOI: 10.1186/s12913-019-3904-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Brunner N, Bruggmann P. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. J Prev Med Public Health 2021;54:251-8. [PMID: 34370938 DOI: 10.3961/jpmph.21.151] [Reference Citation Analysis]
22 Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc 2019;22 Suppl 6:e25348. [PMID: 31468692 DOI: 10.1002/jia2.25348] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
23 Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract 2021;16:52. [PMID: 34384494 DOI: 10.1186/s13722-021-00260-8] [Reference Citation Analysis]
24 Hariri S, Sharafkhah M, Alavi M, Roshandel G, Fazel A, Amiriani T, Motamed-Gorji N, Bazazan A, Merat S, Poustchi H, Malekzadeh R. A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting. Harm Reduct J 2020;17:56. [PMID: 32795371 DOI: 10.1186/s12954-020-00400-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lacoin L, Hurst M, Hill NR, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D. Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. BMJ Open 2019;9:e029066. [PMID: 31383704 DOI: 10.1136/bmjopen-2019-029066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Gao LH, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med 2021;14:289-301. [PMID: 33536776 DOI: 10.2147/IJGM.S283910] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 El-Bitar AMH, Sarhan M, Abdel-Rahman MA, Quintero-Hernandez V, Aoki-Utsubo C, Moustafa MA, Possani LD, Hotta H. Smp76, a Scorpine-Like Peptide Isolated from the Venom of the Scorpion Scorpio maurus palmatus, with a Potent Antiviral Activity Against Hepatitis C Virus and Dengue Virus. Int J Pept Res Ther 2020;26:811-21. [PMID: 32435168 DOI: 10.1007/s10989-019-09888-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother 2018;62:e01620-17. [PMID: 29084747 DOI: 10.1128/AAC.01620-17] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
29 Falade-Nwulia O. Hepatitis C Virus Elimination Requires More Than Good Drugs. Clin Infect Dis 2020;71:1269-70. [PMID: 31563937 DOI: 10.1093/cid/ciz963] [Reference Citation Analysis]
30 Rizk C, Miceli J, Shiferaw B, Malinis M, Barakat L, Ogbuagu O, Villanueva M. Implementing a Comprehensive HCV Clinic within an HIV Clinic: A Model of Care for HCV Micro-elimination. Open Forum Infect Dis. 2019;Online ahead of print. [PMID: 31412130 DOI: 10.1093/ofid/ofz361] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
31 Chen YC, Thio CL, Cox AL, Ruhs S, Kamangar F, Wiberg KJ. Trends in hepatitis C treatment initiation among HIV/hepatitis C virus-coinfected men engaged in primary care in a multisite community health centre in Maryland: a retrospective cohort study. BMJ Open 2019;9:e027411. [PMID: 30928964 DOI: 10.1136/bmjopen-2018-027411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 El-Tahan RR, Ghoneim AM, Zaghloul H. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients. Virus Genes 2020;56:564-81. [PMID: 32572756 DOI: 10.1007/s11262-020-01776-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Janczewska E, Kołek MF, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Zarębska-Michaluk D, Buczyńska I, Dybowska D, Czauż-Andrzejuk A, Berak H, Krygier R, Jaroszewicz J, Citko J, Piekarska A, Dobracka B, Socha Ł, Deroń Z, Laurans Ł, Białkowska-Warzecha J, Tronina O, Adamek B, Tomasiewicz K, Simon K, Pawłowska M, Halota W, Flisiak R. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. World J Gastroenterol 2021; 27(18): 2177-2192 [PMID: 34025072 DOI: 10.3748/wjg.v27.i18.2177] [Reference Citation Analysis]
34 Hsieh YC, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin SM, Tai DI, Lin CY, Sheen IS. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. PLoS One 2018;13:e0202777. [PMID: 30138456 DOI: 10.1371/journal.pone.0202777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Chiu SM, Tsai MC, Lin CY, Chen CH, Lu SN, Hung CH, Sheen IS, Chien RN, Lin CL, Hu TH, Cheng YF, Chen CL. Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment. PLoS One 2020;15:e0231102. [PMID: 32287280 DOI: 10.1371/journal.pone.0231102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Takeda H, Yamashita T, Ueda Y, Sekine A. Exploring the hepatitis C virus genome using single molecule real-time sequencing. World J Gastroenterol 2019; 25(32): 4661-4672 [PMID: 31528092 DOI: 10.3748/wjg.v25.i32.4661] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Kyuregyan KK, Malinnikova EY, Soboleva NV, Isaeva OV, Karlsen AA, Kichatova VS, Potemkin IA, Schibrik EV, Gadjieva OA, Bashiryan BA, Lebedeva NN, Serkov IL, Yankina A, Galli C, Mikhailov MI. Community screening for hepatitis C virus infection in a low-prevalence population. BMC Public Health 2019;19:1038. [PMID: 31375104 DOI: 10.1186/s12889-019-7388-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Wong A, Tsien C, Mansour S, Cooper C. Remaining clinical issues in hepatitis C treatment. CanLivJ 2018;1:66-77. [DOI: 10.3138/canlivj.1.2.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Chen S, Mao W, Guo L, Zhang J, Tang S. Combating hepatitis B and C by 2030: achievements, gaps, and options for actions in China. BMJ Glob Health 2020;5:e002306. [PMID: 32605935 DOI: 10.1136/bmjgh-2020-002306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
40 Tse CS, Yang JD, Mousa OY, Nelson KM, Pungpapong S, Keaveny A, Aqel BA, Vargas H, Dickson RC, Watt K, Gores GJ, Roberts LR, Leise MD. Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplant Direct 2021;7:e635. [PMID: 33324740 DOI: 10.1097/TXD.0000000000001049] [Reference Citation Analysis]
41 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
42 Villegas-galaviz J, Anderson E, Guglin M. Clinical outcomes of heart transplantation using hepatitis c-viremic donors: a systematic review with meta-analysis. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.01.010] [Reference Citation Analysis]
43 Serumondo J, Penkunas MJ, Niyikora J, Ngwije A, Kiromera A, Musabeyezu E, Umutesi J, Umuraza S, Musengimana G, Nsanzimana S. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators. BMC Public Health 2020;20:946. [PMID: 32546216 DOI: 10.1186/s12889-020-09000-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Conti BJ, Leicht AS, Kirchdoerfer RN, Sussman MR. Mass spectrometric based detection of protein nucleotidylation in the RNA polymerase of SARS-CoV-2. Commun Chem 2021;4:41. [PMID: 34189273 DOI: 10.1038/s42004-021-00476-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Matthew AN, Zephyr J, Nageswara Rao D, Henes M, Kamran W, Kosovrasti K, Hedger AK, Lockbaum GJ, Timm J, Ali A, Kurt Yilmaz N, Schiffer CA. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. mBio 2020;11:e00172-20. [PMID: 32234812 DOI: 10.1128/mBio.00172-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Wang AE, Hsieh E, Turner BJ, Terrault N. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. J Gen Intern Med 2022. [PMID: 35484367 DOI: 10.1007/s11606-022-07628-9] [Reference Citation Analysis]
47 Wurcel AG, Burke DJ, Wang JJ, Engle B, Noonan K, Knox TA, Kim AY, Linas BP. The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis. J Urban Health 2018;95:467-73. [PMID: 30027427 DOI: 10.1007/s11524-018-0277-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Cordie A, Mohamed R, Sonderup MW, Wendy Spearman C, Medhat MA, Debzi N, Desalegn H, Esmat G. Hepatitis C elimination in Africa: Seizing the moment for hepatitis-C free future. Arab J Gastroenterol 2021;22:249-51. [PMID: 34531133 DOI: 10.1016/j.ajg.2021.07.002] [Reference Citation Analysis]
49 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Reference Citation Analysis]
50 Akiyama MJ, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. Glob Public Health 2021;:1-13. [PMID: 33689563 DOI: 10.1080/17441692.2021.1896763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Front Pharmacol 2020;11:550205. [PMID: 32982753 DOI: 10.3389/fphar.2020.550205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Kannan A, Biswas L, Kumar A, Kurian J, S Nair A, Suresh P, Sadasivan S, Biswas R. Improving Diagnosis of Hepatitis C Virus Infection Using Hepatitis C Core Antigen Testing in a Resource-Poor Setting. Rev Soc Bras Med Trop 2021;54:e02532020. [PMID: 33605377 DOI: 10.1590/0037-8682-0253-2020] [Reference Citation Analysis]
53 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Sukthong P, Poovorawan K, Tangkijvanich P, Poovorawan Y. Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy. PLoS One 2018;13:e0202991. [PMID: 30138441 DOI: 10.1371/journal.pone.0202991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Gayam V, Mandal AK, Khalid M, Mukhtar O, Gill A, Garlapati P, Tiongson B, Sherigar J, Mansour M, Mohanty S. Association Between Vitamin D Levels and Treatment Response to Direct-Acting Antivirals in Chronic Hepatitis C: A Real-World Study. Gastroenterology Res 2018;11:309-16. [PMID: 30116431 DOI: 10.14740/gr1072w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Busschots D, Bielen R, Koc ÖM, Heyens L, Dercon E, Verrando R, Janssens F, Van den Bergh L, Van Lint P, Bruckers L, Nevens F, Robaeys G. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era. BMC Public Health 2021;21:1574. [PMID: 34416867 DOI: 10.1186/s12889-021-11608-9] [Reference Citation Analysis]
56 Madden A, Hopwood M, Neale J, Treloar C. Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs. Patient 2019;12:259-65. [PMID: 30270403 DOI: 10.1007/s40271-018-0332-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
57 Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses 2018;10:E462. [PMID: 30154359 DOI: 10.3390/v10090462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 DeBose-Scarlett A, Balise R, Kwon D, Vadaparampil S, Chen SX, Schiff ER, Ayala GP, Thomas E. Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population. J Transl Med 2018;16:178. [PMID: 29954391 DOI: 10.1186/s12967-018-1555-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Hsu J, Hsu P, Shie C, Chuah S, Wu I, Huang W, Tang S, Tsai K, Kuo L, Ghose S, Hsu J, Shih C. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. Medicina 2022;58:436. [DOI: 10.3390/medicina58030436] [Reference Citation Analysis]
60 Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E2013. [PMID: 30223539 DOI: 10.3390/ijerph15092013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
61 Chaudhury CS, Mee T, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Stanley TL, Hadigan C. Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance. Clin Infect Dis. 2019;69:571-576. [PMID: 30715229 DOI: 10.1093/cid/ciy965] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
62 Njiomegnie GF, Read SA, Fewings N, George J, McKay F, Ahlenstiel G. Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. J Clin Med. 2020;9. [PMID: 32268490 DOI: 10.3390/jcm9041030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
63 Somers N, Vandekerckhove E, Geerts A, Degroote H, Lefere S, Devisscher L, Meuris L, Callewaert N, Van Vlierberghe H, Verhelst X. Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection. Acta Clin Belg 2022;:1-7. [PMID: 35505274 DOI: 10.1080/17843286.2022.2072110] [Reference Citation Analysis]
64 Pascut D, Cavalletto L, Pratama MY, Bresolin S, Trentin L, Basso G, Bedogni G, Tiribelli C, Chemello L. Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. Cancers (Basel) 2019;11:E1773. [PMID: 31717959 DOI: 10.3390/cancers11111773] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
65 Cossiga V, Guarino M, Morisco F, Caporaso N. Risk stratification of HCC occurrence after HCV eradication: a complicate plot of risk factors related and unrelated to the previous viral disease. Hepatobiliary Surg Nutr 2020;9:511-3. [PMID: 32832506 DOI: 10.21037/hbsn.2019.11.27] [Reference Citation Analysis]
66 Rewisha E, Salman T, Alhaddad O, Raia GA, Naguib M, Rashad S, Abdelfattah A, Metwally K, Abdelsameea E. Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients. Clin Exp Hepatol 2021;7:320-7. [PMID: 34712835 DOI: 10.5114/ceh.2021.109293] [Reference Citation Analysis]
67 Solomon SS, Wagner-cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00397-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
69 Ross PE, Young JR, O'Connor CM, Anoushiravani AA, DiCaprio MR. Perioperative Management of Hepatitis C in Patients Undergoing Total Joint Arthroplasty. JBJS Rev 2021;9. [PMID: 34757978 DOI: 10.2106/JBJS.RVW.20.00223] [Reference Citation Analysis]
70 Mafirakureva N, Lim AG, Khalid GG, Aslam K, Campbell L, Zahid H, Van den Bergh R, Falq G, Fortas C, Wailly Y, Auat R, Donchuk D, Loarec A, Coast J, Vickerman P, Walker JG. Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan. J Viral Hepat 2021;28:268-78. [PMID: 33051950 DOI: 10.1111/jvh.13422] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Kim NJ, Magee C, Cummings C, Park H, Khalili M. Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Hepatol Commun 2018;2:1274-83. [PMID: 30288480 DOI: 10.1002/hep4.1246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
72 Rhodes T, Lancaster K. Excitable models: Projections, targets, and the making of futures without disease. Sociol Health Illn 2021;43:859-80. [PMID: 33942914 DOI: 10.1111/1467-9566.13263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Ye Z, Zhang X, Zhang Y, Liu L, Xuan Z, Huang P. Associations of DDX60L With the Clinical Features and Prognosis of Hepatocellular Carcinoma. Front Oncol 2022;12:761021. [DOI: 10.3389/fonc.2022.761021] [Reference Citation Analysis]
74 Mücke MM, Mücke VT, Peiffer KH, Sarrazin C, Zeuzem S, Berger A, Vermehren J. Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study. Open Forum Infect Dis 2019;6:ofy340. [PMID: 30648130 DOI: 10.1093/ofid/ofy340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
75 Muro K, Toda N, Yamamoto S, Yanagita M. The Successful Treatment of a Case of HCV-associated Cryoglobulinemic Glomerulonephritis with Rituximab, Direct-acting Antiviral Agents, Plasmapheresis and Long-term Steroid Despite Serologically Persistent Cryoglobulinemia. Intern Med 2021;60:583-9. [PMID: 32999232 DOI: 10.2169/internalmedicine.5461-20] [Reference Citation Analysis]
76 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
77 Leoni MC, Ustianowski A, Farooq H, Arends JE. HIV, HCV and HBV: A Review of Parallels and Differences. Infect Dis Ther 2018;7:407-19. [PMID: 30182282 DOI: 10.1007/s40121-018-0210-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
78 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
79 Lu MY, Yeh ML, Huang CI, Wang SC, Tsai YS, Tsai PC, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World J Gastroenterol 2022; 28(1): 140-153 [DOI: 10.3748/wjg.v28.i1.140] [Reference Citation Analysis]
80 Patel EU, Solomon SS, Mcfall AM, Srikrishnan AK, Pradeep A, Nandagopal P, Laeyendecker O, Tobian AAR, Thomas DL, Sulkowski MS, Kumar MS, Mehta SH. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. Int J Drug Policy 2018;57:51-60. [PMID: 29679811 DOI: 10.1016/j.drugpo.2018.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
81 Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20-30. [PMID: 30157316 DOI: 10.1111/liv.13949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
82 Arias ABV, Villegas Herrera MT, Arco Sánchez A, Adel ME, Triguero Cabrera J, Plata Illescas C, Montes Osuna MC, Santoyo Villalba J, Villar Del Moral JM. Indication for Liver Transplantation After Direct-Acting Agents in the Treatment of Patients With Hepatitis C. Transplant Proc 2021:S0041-1345(21)00798-3. [PMID: 34911619 DOI: 10.1016/j.transproceed.2021.08.058] [Reference Citation Analysis]
83 Rodriguez C, Soulier A, Demontant V, Poiteau L, Mercier-Darty M, Bouvier-Alias M, Pawlotsky JM, Chevaliez S. A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination. Sci Rep 2018;8:4180. [PMID: 29520035 DOI: 10.1038/s41598-018-22614-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
84 Adee M, Zhuo Y, Zhong H, Zhan T, Aggarwal R, Shilton S, Chhatwal J. Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator. Sci Rep 2021;11:21382. [PMID: 34725356 DOI: 10.1038/s41598-021-00362-y] [Reference Citation Analysis]
85 Hara T, Ohara T, Taniguchi M, Sakai T, Oka K, Iwai N, Tsuji T, Okuda T, Komaki T, Sakagami J, Kagawa K. Development of Hepatocellular Carcinoma in a Patient with Chronic Hepatitis C 21 Years after Achieving a Sustained Virological Response to Interferon Therapy. Case Reports Hepatol 2020;2020:8824974. [PMID: 33123390 DOI: 10.1155/2020/8824974] [Reference Citation Analysis]
86 Beste LA, Zhang X, Su GL, Van T, Ioannou GN, Oselio B, Tincopa M, Liu B, Singal AG, Zhu J, Waljee AK. Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort. BMC Med Inform Decis Mak 2021;21:347. [PMID: 34903225 DOI: 10.1186/s12911-021-01711-7] [Reference Citation Analysis]
87 Cowton VM, Owsianka AM, Fadda V, Ortega-Prieto AM, Cole SJ, Potter JA, Skelton JK, Jeffrey N, Di Lorenzo C, Dorner M, Taylor GL, Patel AH. Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. NPJ Vaccines 2021;6:7. [PMID: 33420102 DOI: 10.1038/s41541-020-00269-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Rossi C, Young J, Martel-Laferrière V, Walmsley S, Cooper C, Wong A, Gill MJ, Klein MB; Canadian Co-Infection Cohort Investigators . Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. Open Forum Infect Dis 2019;6:ofz055. [PMID: 30882016 DOI: 10.1093/ofid/ofz055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
89 Verma M, Chu JN, Salama JAF, Faiz MT, Eweje F, Gwynne D, Lopes A, Hess K, Soares V, Steiger C, McManus R, Koeppen R, Hua T, Hayward A, Collins J, Tamang SM, Ishida K, Miller JB, Katz S, Slocum AH, Sulkowski MS, Thomas DL, Langer R, Traverso G. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. Proc Natl Acad Sci U S A 2020;117:11987-94. [PMID: 32424082 DOI: 10.1073/pnas.2004746117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS One 2018;13:e0207226. [PMID: 30500863 DOI: 10.1371/journal.pone.0207226] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
91 Falade-Nwulia O, Sacamano P, McCormick SD, Yang C, Kirk G, Thomas D, Sulkowski M, Latkin C, Mehta SH. Individual and network factors associated with HCV treatment uptake among people who inject drugs. Int J Drug Policy 2020;78:102714. [PMID: 32135398 DOI: 10.1016/j.drugpo.2020.102714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
92 Zullig LL, Bhatia HL, Gellad ZF, Eatherly M, Henderson R, Bosworth HB. Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study. BMC Health Serv Res 2019;19:521. [PMID: 31345218 DOI: 10.1186/s12913-019-4349-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
93 Grant P, Shumbusho F, Van Nuil JI, Kateera F, Mukherjee J, Kabahizi J, Ntaganda F, Nsanzimana S, Mbituyumuremyi A, Damascene MJ, Muvunyi CM, Mukabatsinda C, Musabeyezu E, Ntirenganya C, Gupta N. Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. Hepatol Commun 2020;4:569-76. [PMID: 32258951 DOI: 10.1002/hep4.1482] [Reference Citation Analysis]
94 Chan A, Park L, Collins LF, Cooper C, Saag M, Dieterich D, Sulkowski M, Naggie S. Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort. Open Forum Infect Dis 2019;6:ofy273. [PMID: 30697570 DOI: 10.1093/ofid/ofy273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infect Dis 2018;18:223. [PMID: 29769038 DOI: 10.1186/s12879-018-3125-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
96 Grebely J, Tran L, Degenhardt L, Dowell-Day A, Santo T, Larney S, Hickman M, Vickerman P, French C, Butler K, Gibbs D, Valerio H, Read P, Dore GJ, Hajarizadeh B. Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. Clin Infect Dis 2021;73:e107-18. [PMID: 32447375 DOI: 10.1093/cid/ciaa612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
97 Bakhai S, Nallapeta N, El-Atoum M, Arya T, Reynolds JL. Improving hepatitis C screening and diagnosis in patients born between 1945 and 1965 in a safety-net primary care clinic. BMJ Open Qual 2019;8:e000577. [PMID: 31637319 DOI: 10.1136/bmjoq-2018-000577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
98 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
99 Rusere LN, Matthew AN, Lockbaum GJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants. ACS Med Chem Lett 2018;9:691-6. [PMID: 30034602 DOI: 10.1021/acsmedchemlett.8b00150] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
100 Cai D, Liu L, Tian B, Fu X, Yang Q, Chen J, Zhang Y, Fang J, Shen L, Wang Y, Gou L, Zuo Z. Dual-Role Ubiquitination Regulation Shuttling the Entire Life Cycle of the Flaviviridae. Front Microbiol 2022;13:835344. [DOI: 10.3389/fmicb.2022.835344] [Reference Citation Analysis]
101 Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M. Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment. J Clin Exp Hepatol 2020;10:114-23. [PMID: 32189926 DOI: 10.1016/j.jceh.2019.09.001] [Reference Citation Analysis]
102 Pruß A, Chandrasekar A, Sánchez-Ibáñez J, Lucas-Samuel S, Kalus U, Rabenau HF. Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus. Transfus Med Hemother 2021;48:12-22. [PMID: 33708048 DOI: 10.1159/000513179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Havens JR, Schaninger T, Fraser H, Lofwall M, Staton M, Young AM, Hoven A, Walsh SL, Vickerman P. Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. BMJ Open 2021;11:e041490. [PMID: 34226208 DOI: 10.1136/bmjopen-2020-041490] [Reference Citation Analysis]
104 Falade-Nwulia O, Sulkowski MS. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. J Infect Dis 2020;222:S745-57. [PMID: 33245350 DOI: 10.1093/infdis/jiaa534] [Reference Citation Analysis]
105 Radwan D, Cachay E, Falade-Nwulia O, Moore RD, Westergaard R, Mathews WC, Aberg J, Cheever L, Gebo KA; HIV Research Network. HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015. J Acquir Immune Defic Syndr 2019;80:559-67. [PMID: 30649030 DOI: 10.1097/QAI.0000000000001949] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
106 Kim NJ, Pearson M, Vutien P, Su F, Moon AM, Berry K, Green PK, Williams EC, Ioannou GN. Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment. Hepatol Commun 2020;4:314-24. [PMID: 32025613 DOI: 10.1002/hep4.1464] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Tsai WL, Wang CF, Cheng JS, Chen WC, Bair MJ, Lo CC. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. PLoS One 2020;15:e0227424. [PMID: 31923251 DOI: 10.1371/journal.pone.0227424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Oberemok VV, Laikova KV, Yurchenko KA, Marochkin NA, Fomochkina II, Kubyshkin AV. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus. Inflamm Res 2020;69:801-12. [PMID: 32656668 DOI: 10.1007/s00011-020-01377-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
109 Park H, Song HJ, Jiang X, Henry L, Cook RL, Nelson DR. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C. Hepatol Commun 2021;5:203-16. [PMID: 33553969 DOI: 10.1002/hep4.1634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
110 Yue M, Tian T, Wang C, Fan H, Wu J, Wang J, Li J, Xia X, Zhang A, Yu R, Zhang Y, Huang P. Genetic mutations in NF-κB pathway genes were associated with the protection from hepatitis C virus infection among Chinese Han population. Sci Rep 2019;9:10830. [PMID: 31346215 DOI: 10.1038/s41598-019-47058-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 Baharlou R, Romani B, Kiani SJ, Sadeghi K, Shadmand E, Fazel H, Jalilian FA, Kord E, Yaghoubi S, Nikmanesh Y, Ahmadi Vasmehjani A. Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients. Med Microbiol Immunol 2018;207:65-74. [PMID: 29147974 DOI: 10.1007/s00430-017-0527-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
112 Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration. BMC Nurs 2019;18:23. [PMID: 31210751 DOI: 10.1186/s12912-019-0347-x] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
113 Park H, Jiang X, Song HJ, Lo Re V 3rd, Childs-Kean LM, Lo-Ciganic WH, Cook RL, Nelson DR. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. Hepatology 2021;74:566-81. [PMID: 33544904 DOI: 10.1002/hep.31732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Zhao Q, Jiang S, Li M, Yao L, Ma X, Li M, Wang C, Pan Y, Zhao H, Li B. Incidence trend and age-period-cohort analysis of reported hepatitis C among residents aged 30 to 79 in northeastern China, 2008 to 2017. Medicine (Baltimore) 2020;99:e22005. [PMID: 32899048 DOI: 10.1097/MD.0000000000022005] [Reference Citation Analysis]
115 Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med 2018;16:175. [PMID: 30296935 DOI: 10.1186/s12916-018-1162-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
116 El-Shamy A, Branch AD, Schiano TD, Gorevic PD. The Complement System and C1q in Chronic Hepatitis C Virus Infection and Mixed Cryoglobulinemia. Front Immunol 2018;9:1001. [PMID: 29910796 DOI: 10.3389/fimmu.2018.01001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
117 Morisco F, Federico A, Marignani M, Cannavò M, Pontillo G, Guarino M, Dallio M, Begini P, Benigno RG, Lombardo FL, Stroffolini T. Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. Cancers (Basel) 2021;13:3810. [PMID: 34359711 DOI: 10.3390/cancers13153810] [Reference Citation Analysis]
118 Mazzarella C, Rocco C, Vallefuoco L, Sorrentino R, Braschi U, Lauritano G, Di Biase A, Misso S, Portella G. Differential reactivity of anti-hepatitis C virus screening assays in patients with waning antibodies. Future Virology 2019;14:303-9. [DOI: 10.2217/fvl-2018-0195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
119 Hara T, Ohara T, Taniguchi M, Sakai H, Oka K, Iwai N, Tsuji T, Okuda T, Nagata A, Komaki T, Sakagami J, Kagawa K. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection. Intern Med 2021;60:2437-43. [PMID: 33612683 DOI: 10.2169/internalmedicine.6664-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Watts T, Lauver D, Sethi AK, Snedden T, Zahner S. Hepatitis C virus infections among people aged 15-44, United States, 2009-2018. Public Health Nurs 2021;38:167-75. [PMID: 32935390 DOI: 10.1111/phn.12808] [Reference Citation Analysis]
121 Prinsenberg T, Zantkuijl P, Zuilhof W, Davidovich U, Schinkel J, Prins M, van der Valk M. Design and Implementation of a Multilevel Intervention to Reduce Hepatitis C Transmission Among Men Who Have Sex With Men in Amsterdam: Co-Creation and Usability Study. JMIR Form Res 2020;4:e19100. [PMID: 32915157 DOI: 10.2196/19100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Falade-Nwulia O, Ward KM, McCormick S, Mehta SH, Pitts SR, Katz S, Chander G, Thomas DL, Sulkowski M, Latkin CA. Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. J Viral Hepat 2020;27:663-70. [PMID: 32045086 DOI: 10.1111/jvh.13274] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
123 Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infect Dis 2018;5:ofy120. [PMID: 29992173 DOI: 10.1093/ofid/ofy120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
124 Angeletti A, Cantarelli C, Cravedi P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front Med (Lausanne) 2019;6:20. [PMID: 30800660 DOI: 10.3389/fmed.2019.00020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
125 Ji D, Chen GF, Niu XX, Zhang M, Wang C, Shao Q, Wu V, Wang Y, Cheng G, Hurwitz SJ, Schinazi RF, Lau G. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090. [PMID: 33889834 DOI: 10.1016/j.metop.2021.100090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
126 Nguyen N, Patel K, Uhelski AC, Waters B, Weir A. Antiviral Therapy Improves Hepatocellular Cancer Survival. Fed Pract 2021;38:e58-63. [PMID: 34733098 DOI: 10.12788/fp.0165] [Reference Citation Analysis]
127 Nguang SH, Wu CK, Liang CM, Tai WC, Yang SC, Ku MK, Yuan LT, Wang JW, Tseng KL, Hung TH, Hsu PI, Wu DC, Chuah SK, Hsu CN. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan. Int J Environ Res Public Health 2018;15:E2655. [PMID: 30486324 DOI: 10.3390/ijerph15122655] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
128 Pal V, Ancha N, Mann J, Modi AA. Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response. Can J Gastroenterol Hepatol 2020;2020:8815829. [PMID: 32802821 DOI: 10.1155/2020/8815829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Pearce ME, Bartlett SR, Yu A, Lamb J, Reitz C, Wong S, Alvarez M, Binka M, Velásquez Garcia H, Jeong D, Clementi E, Adu P, Samji H, Wong J, Buxton J, Yoshida E, Elwood C, Sauve L, Pick N, Krajden M, Janjua NZ. Women in the 2019 hepatitis C cascade of care: findings from the British Columbia Hepatitis Testers cohort study. BMC Womens Health 2021;21:330. [PMID: 34511082 DOI: 10.1186/s12905-021-01470-7] [Reference Citation Analysis]
130 Tagliapietra M, Monaco S. Neuroimaging Findings in Chronic Hepatitis C Virus Infection: Correlation with Neurocognitive and Neuropsychiatric Manifestations. Int J Mol Sci. 2020;21. [PMID: 32252497 DOI: 10.3390/ijms21072478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
131 Ho TY, Liu S, Zabinsky ZB. A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management. Health Care Manag Sci 2019;22:727-55. [PMID: 30194509 DOI: 10.1007/s10729-018-9454-6] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
132 Alshuwaykh O, Kwo PY. Current and future strategies for the treatment of chronic hepatitis C. Clin Mol Hepatol 2021;27:246-56. [PMID: 33317245 DOI: 10.3350/cmh.2020.0230] [Reference Citation Analysis]
133 Ng M, Hayashi K, Voon P, Shulha HP, DeBeck K, Milloy MJ, Ti L. Characterising the association between positive hepatitis C virus antibody and pain among people who inject drugs. Drug Alcohol Rev 2019;38:639-43. [PMID: 31418953 DOI: 10.1111/dar.12969] [Reference Citation Analysis]
134 Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, Dos Santos AGP, Xue Z, Trinh R, Porcalla A, Zeuzem S. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. Adv Ther 2019;36:3458-70. [PMID: 31646465 DOI: 10.1007/s12325-019-01123-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
135 Perazzo H, Castro R, Luz PM, Banholi M, Goldenzon RV, Cardoso SW, Grinsztejn B, Veloso VG. Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. Bull World Health Organ 2020;98:188-197K. [PMID: 32132753 DOI: 10.2471/BLT.19.231522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
136 Ward KM, McCormick SD, Sulkowski M, Latkin C, Chander G, Falade-Nwulia O. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. Int J Drug Policy 2021;88:103019. [PMID: 33160152 DOI: 10.1016/j.drugpo.2020.103019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Ragusa R, Corsaro LS, Frazzetto E, Bertino E, Bellia MA, Bertino G. Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments. AJP Rep 2020;10:e121-7. [PMID: 32257593 DOI: 10.1055/s-0040-1709185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
138 Ozeki I, Nakajima T, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y. Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc. J Clin Biochem Nutr 2020;66:245-52. [PMID: 32523252 DOI: 10.3164/jcbn.19-98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
139 Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25:220-227. [PMID: 29316030 DOI: 10.1111/jvh.12859] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
140 Wang Q, Hagedorn C, Liu S. Adapted HCV JFH1 variant is capable of accommodating a large foreign gene insert and allows lower level HCV replication and viral production. Int J Biol Sci 2018;14:1211-20. [PMID: 30123070 DOI: 10.7150/ijbs.27411] [Reference Citation Analysis]
141 Bamba M, Bordage S, Sahuc M, Moureu S, Samaillie J, Roumy V, Vauchel P, Dimitrov K, Rouillé Y, Dubuisson J, Tra Bi FH, Séron K, Sahpaz S. Anti-HCV Tannins From Plants Traditionally Used in West Africa and Extracted With Green Solvents. Front Pharmacol 2022;12:789688. [DOI: 10.3389/fphar.2021.789688] [Reference Citation Analysis]
142 McClure MW, Berliba E, Tsertsvadze T, Streinu-Cercel A, Vijgen L, Astruc B, Patat A, Westland C, Chanda S, Zhang Q, Kakuda TN, Vuong J, Khorlin N, Beigelman L, Blatt LM, Fry J. Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. PLoS One 2018;13:e0204974. [PMID: 30325939 DOI: 10.1371/journal.pone.0204974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
143 Hosui A, Tanimoto T, Okahara T, Ashida M, Ohnishi K, Wakahara Y, Kusumoto Y, Yamaguchi T, Sueyoshi Y, Hirao M, Yamada T, Hiramatsu N. Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA. Hepatol Commun 2021;5:2001-8. [PMID: 34752016 DOI: 10.1002/hep4.1782] [Reference Citation Analysis]
144 Martínez-Rebollar M, De La Mora L, Campistol M, Cabrera B, Bagué A, De Lazzari E, Torres B, González-Cordón A, Inciarte A, Ambrosioni J, Martínez E, Blanco JL, Forns X, Blanch J, Mallolas J, Laguno M. Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. Infect Dis Ther 2021;10:1253-66. [PMID: 33914265 DOI: 10.1007/s40121-021-00448-0] [Reference Citation Analysis]
145 Blanding DP, Moran WP, Bian J, Zhang J, Marsden J, Mauldin PD, Rockey DC, Schreiner AD. Linkage to specialty care in the hepatitis C care cascade. J Investig Med 2021;69:324-32. [PMID: 33203787 DOI: 10.1136/jim-2020-001521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Hassany SM, Hassan W, Abo-Alam H, Khalaf M, Nafeh AM, Nasr-Eldin E, Mostafa EF. Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed. Infect Drug Resist 2020;13:1873-80. [PMID: 32606836 DOI: 10.2147/IDR.S241948] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
148 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1948-5182')">Reference Citation Analysis]
149 Falade-Nwulia O, Sutcliffe CG, Mehta SH, Moon J, Chander G, Keruly J, Katzianer J, Thomas DL, Moore RD, Sulkowski MS. Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum. Open Forum Infect Dis 2019;6:ofz426. [PMID: 31667200 DOI: 10.1093/ofid/ofz426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
150 Cooper CL, Read D, Vachon ML, Conway B, Wong A, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld JJ, Lee S; CANUHC Cohort. Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. BMC Public Health 2020;20:1345. [PMID: 32883249 DOI: 10.1186/s12889-020-09464-0] [Reference Citation Analysis]
151 Walker A, Boyce A, Duggal P, Thio CL, Geller G. The Ethics of Precision Rationing: Human Genetics and the Need for Debate on Stratifying Access to Medication. Public Health Genomics 2020;23:149-54. [PMID: 32516789 DOI: 10.1159/000508141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 van Buuren N, Tellinghuisen TL, Richardson CD, Kirkegaard K. Transmission genetics of drug-resistant hepatitis C virus. Elife 2018;7:e32579. [PMID: 29589830 DOI: 10.7554/eLife.32579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
153 Choi GH, Jang ES, Kim JW, Jeong SH. A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea. Gut Liver 2020;14:808-16. [PMID: 32066209 DOI: 10.5009/gnl19296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Shoukry NH. Hepatitis C Vaccines, Antibodies, and T Cells. Front Immunol 2018;9:1480. [PMID: 30002657 DOI: 10.3389/fimmu.2018.01480] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
155 Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res 2019;19:765. [PMID: 31660966 DOI: 10.1186/s12913-019-4635-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
156 Litaker JR, Tamez N, Lopez Bray C, Allison RD, Durkalski W, Taylor R. Hepatitis C Antibody Screening Among Baby Boomers by a Community-Based Health Insurance Company. Popul Health Manag 2021;24:492-5. [PMID: 33197366 DOI: 10.1089/pop.2020.0214] [Reference Citation Analysis]
157 Rout G, Nayak B, Patel AH, Gunjan D, Singh V, Kedia S, Shalimar. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography. J Clin Exp Hepatol 2019;9:207-14. [PMID: 31024203 DOI: 10.1016/j.jceh.2018.06.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
158 Prouté M, Le Coeur S, Tiv MH, Dub T, Jongpaijitsakul P, Ratnamhin A, Angkurawaranon C, Aramrattana A, Lallemant M. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs. BMC Public Health 2020;20:1450. [PMID: 32972359 DOI: 10.1186/s12889-020-09549-w] [Reference Citation Analysis]
159 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
160 Timm J, Kosovrasti K, Henes M, Leidner F, Hou S, Ali A, Kurt Yilmaz N, Schiffer CA. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir. ACS Chem Biol 2020;15:342-52. [PMID: 31868341 DOI: 10.1021/acschembio.9b00675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
161 Matli VVK, Dhahri A, Boda Eswara V, Green LD. Chest Wall Swelling in a Baby Boomer: An Unusual Presentation of Primary Hepatocellular Carcinoma. Cureus 2021;13:e18163. [PMID: 34567914 DOI: 10.7759/cureus.18163] [Reference Citation Analysis]
162 Al Moussawi H, Polavarapu AD, Asti D, Awada Z, Mulrooney S. Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor. Case Rep Gastroenterol 2018;12:629-32. [PMID: 30483041 DOI: 10.1159/000493421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 van Dijk M, Drenth JPH; HepNed study group. Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination. J Viral Hepat 2020;27:1270-83. [PMID: 32964615 DOI: 10.1111/jvh.13399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
164 Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis 2018;5:ofy076. [PMID: 29977955 DOI: 10.1093/ofid/ofy076] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 10.5] [Reference Citation Analysis]
165 Fawsitt CG, Vickerman P, Cooke GS, Welton NJ; STOP HCV Consortium. Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. Value Health 2020;23:180-90. [PMID: 32113623 DOI: 10.1016/j.jval.2019.08.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
167 Cox A, Sulkowski M, Sugarman J. Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. Clin Infect Dis 2020;71:2986-90. [PMID: 32442262 DOI: 10.1093/cid/ciaa640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Huang YT, Hsieh YY, Chen WM, Tung SY, Wei KL, Shen CH, Chang KC, Lu CK, Yen CW, Lu SN, Hung CH, Chang TS. Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol 2021;21:259. [PMID: 34118889 DOI: 10.1186/s12876-021-01837-y] [Reference Citation Analysis]
169 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
170 Falade-Nwulia O, Irvin R, Merkow A, Sulkowski M, Niculescu A, Olsen Y, Stoller K, Thomas DL, Latkin C, Mehta SH. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat 2019;100:45-51. [PMID: 30898327 DOI: 10.1016/j.jsat.2019.01.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
171 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
172 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Poovorawan Y. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study. PLoS One 2018;13:e0196301. [PMID: 29689073 DOI: 10.1371/journal.pone.0196301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
173 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
174 Osborne W, Sheikh N, Botterill G, Bufton S, Mutimer D, Tahir M, Atabani SF. An experience using historical hepatitis C data to Re-Engage: Possibilities and pitfalls during the COVID-19 pandemic. Public Health Pract (Oxf) 2021;2:100207. [PMID: 34723230 DOI: 10.1016/j.puhip.2021.100207] [Reference Citation Analysis]
175 Piedade J, Pereira G, Guimarães L, Duarte J, Victor L, Baldin C, Inacio C, Santos R, Chaves Ú, Nunes EP, Grinsztejn B, Veloso VG, Fernandes F, Perazzo H. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. Sci Rep 2021;11:11681. [PMID: 34083617 DOI: 10.1038/s41598-021-91099-1] [Reference Citation Analysis]
176 Karmarkar T, Rodriguez-Watson CV, Watson E, Zheng H, Gaskin DJ, Padula WV. Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis. Value Health 2022:S1098-3015(22)00145-0. [PMID: 35484030 DOI: 10.1016/j.jval.2022.03.003] [Reference Citation Analysis]
177 Paul Noel B, Peter C, Emma R, Asthika A, Francis DJ. Cohort study: Apparent redundancy of fibrosis assessment in young persons with HCV; development of realistic approaches to break the paradigm. Ann Hepatol 2021;27:100550. [PMID: 34606981 DOI: 10.1016/j.aohep.2021.100550] [Reference Citation Analysis]
178 Li J, Armon C, Palella FJ, Tedaldi E, Novak RM, Fuhrer J, Simoncini G, Carlson K, Buchacz K; HIV Outpatient Study (HOPS) Investigators . Hepatitis C Virus Testing Among Men With Human Immunodeficiency Virus Who Have Sex With Men: Temporal Trends and Racial/Ethnic Disparities. Open Forum Infect Dis 2021;8:ofaa645. [PMID: 33889655 DOI: 10.1093/ofid/ofaa645] [Reference Citation Analysis]
179 O'Neil CR, Buss E, Plitt S, Osman M, Coffin CS, Charlton CL, Shafran S. Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada. Can J Public Health 2019;110:714-21. [PMID: 31222618 DOI: 10.17269/s41997-019-00234-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
180 Besombes J, Pronier C, Lefevre C, Lagathu G, Maillard A, Grolhier C, Thibault V. Performances of NeuMoDx™, a random-access system for hepatitis B virus DNA and hepatitis C virus RNA quantification. Clin Microbiol Infect 2021;27:1693.e9-1693.e15. [PMID: 33677082 DOI: 10.1016/j.cmi.2021.02.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
182 Shirasaki T, Honda M, Yamashita T, Nio K, Shimakami T, Shimizu R, Nakasyo S, Murai K, Shirasaki N, Okada H, Sakai Y, Sato T, Suzuki T, Yoshioka K, Kaneko S. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Sci Rep 2018;8:13143. [PMID: 30177680 DOI: 10.1038/s41598-018-31421-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
183 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Reference Citation Analysis]
184 Dawe J, Wilkinson AL, Asselin J, Carter A, Pedrana A, Traeger MW, Thomas AJ, Curtis M, Cooper M, Howell J, Doyle JS, Hellard ME, Stoové M. Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020. International Journal of Drug Policy 2022;104:103696. [DOI: 10.1016/j.drugpo.2022.103696] [Reference Citation Analysis]